Image pharmaphorum Editor News NICE approves neuroblastoma immunotherapy drug for NHS use NICE has approved a drug to treat children with high-risk neuroblastoma within the NHS in England and Wales. News Prostate drug approved for use in non-metastatic cases The US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic prostate cancer. News Type 2 diabetes research: fewer side effects from modified m... Scientists have made progress in the quest to find medication for Type 2 diabetes that causes fewer side effects than current treatments. News China strives to lower cost of cancer drugs as disease rates... China is pushing domestic and overseas markets to lower the cost of cancer drugs to make them more accessible. Load more results
News NICE approves neuroblastoma immunotherapy drug for NHS use NICE has approved a drug to treat children with high-risk neuroblastoma within the NHS in England and Wales.
News Prostate drug approved for use in non-metastatic cases The US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic prostate cancer.
News Type 2 diabetes research: fewer side effects from modified m... Scientists have made progress in the quest to find medication for Type 2 diabetes that causes fewer side effects than current treatments.
News China strives to lower cost of cancer drugs as disease rates... China is pushing domestic and overseas markets to lower the cost of cancer drugs to make them more accessible.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
